Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 118, 104597
Abstract
No abstract availableKeywords
Funding Information
- Cairo University
- National Cancer Institute, Cairo University
This publication has 21 references indexed in Scilit:
- CD123 and its potential clinical application in leukemiasLife Sciences, 2015
- New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized MedicineClinical Cancer Research, 2014
- CD 123 is a membrane biomarker and a therapeutic target in hematologic malignanciesBiomarker Research, 2014
- Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemiaTumor Biology, 2012
- Expression of CD200 on AML blasts directly suppresses memory T-cell functionLeukemia, 2012
- CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumorOncogene, 2011
- CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemiaLeukemia, 2011
- The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: A Children's Oncology Group studyPediatric Blood & Cancer, 2010
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem CellsCell Stem Cell, 2009
- Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosisBlood, 2002